You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Request a contact

Stay informed

Live Chat

Indications

Active ingredients of Anoro Ellipta [1]

Anoro Ellipta (umeclidinium bromide/vilanterol [as trifenatate]) inhalation powder

Each single inhalation of umeclidinium bromide (UMEC) 62.5 micrograms (mcg) and vilanterol (VI) 25mcg provides a delivered dose of UMEC 55mcg and VI 22mcg.

COPD

Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).[1]

Innoviva logo

Reference:

  1. Anoro Ellipta 52/22 mcg SPC; GlaxoSmithKline 2017

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Anoro and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies